Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease

Wu, Ruey Meei; Chiu, Hsiu‐Hui; Wang, M.; Chen, R. C.

doi:10.1007/bf02251203

Cited by 13 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have also shown that the dyskinesias and the motor fluctuations correlated with the duration of levodopa treatment rather than the duration of the disease (Rajput et al ., 1984; Leenders et al ., 1986; Melamed, 1986; Denny and Begari, 1999; Grandas et al ., 1999), although others failed to prove such relationship (Fahn and Bressman, 1984; Horstink et al ., 1990; Fahn, 1996). The exact contribution of the levodopa dose remains controversial (Fahn and Bressman, 1984; Peppe et al ., 1993; Wu et al ., 1993), but a chronic low dose regimen has been linked to a lower incidence of dyskinesias (Rajput et al ., 1984; Poewe et al ., 1986). Three groups of patients in our study did not differ significantly in daily doses of levodopa at the emergence of dyskinesias (Table 1).…”

Section: Discussionmentioning

confidence: 99%

The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications

Kostić¹,

Marinković²,

Svetel³

et al. 2002

Euro J of Neurology

View full text Add to dashboard Cite

The aim of this study was to ascertain whether the stage of Parkinson's disease (PD) (according to the Hoehn and Yahr staging system) would affect the length of time between the introduction of levodopa therapy and appearance of levodopa-associated motor complications. Forty patients with clinically definite PD were studied. In all, clinical and therapeutic data were collected from the time of diagnosis to the time of levodopa-associated motor complications (i.e. dyskinesia, motor fluctuations). In 17 patients, levodopa could be started in Hoehn and Yahr stage I (H & Y-I; 16.2 months after the onset of PD), whilst in 13 patients levodopa could be started in H & Y-II (19.6 months after the onset of the disease) and in 10 in H & Y-III (45.1 months after the onset of PD). Cox proportional hazard regression model shows that the PD patients in whom the initial levodopa treatment was introduced at stage III develop both dyskinesias and motor fluctuations significantly earlier than the patients whose levodopa started in stage I and II of PD. The median interval to develop dyskinesias was 66, 72 and 24 months for patients in whom levodopa was introduced in stage I, II and III, respectively. These values were 64, 55 and 14 months for motor fluctuations. These findings add to the clinical arguments that favour an essential role of severity of PD at levodopa initiation as a risk factor for the development of levodopa-associated motor complications.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications

Kostić¹,

Marinković²,

Svetel³

et al. 2002

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…Other risk factors are an early age at disease onset and a high cumulative dose and duration of levodopa treatment (Grandas et al, 1999;Sharma et al, 2010;Wu et al, 1993). It has also been reported that females have a higher risk of this motor complication, although this is not consistent across studies (Lyons et al, 1998;Van Garpen et al, 2006;Zappia et al, 2005).…”

Section: Clinico-demographic Factorsmentioning

confidence: 94%

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Jiménez-Urbieta

Gago

Riva

et al. 2015

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…In addition to the increased likelihood that younger‐onset patients with PD are male,36‐38,41 younger‐onset PD patients also experience more extrapyramidal motor side effects when treated,36,41‐45 suggesting an elevated susceptibility of the basal ganglia to treatment‐associated toxicity. Like PD, DLB also has a male predominance in younger age cohorts (under 70)46 and the presence of extrapyramidal symptoms is one of the diagnostic criteria used in diagnosing DLB.…”

Section: Introductionmentioning

confidence: 99%

Brain Ferritin Iron as a Risk Factor for Age at Onset in Neurodegenerative Diseases

Bartzokis

Tishler

Shin

et al. 2004

Annals of the New York Academy of Sciences

169

View full text Add to dashboard Cite

Tissue iron can promote oxidative damage. Brain iron increases with age and is abnormally elevated early in the disease process in several neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). Higher iron levels in males may contribute to higher risk for younger-onset PD and recent studies have linked the presence of the hemochromatosis gene with a younger age at onset of AD. We examined whether age at onset of PD and AD was associated with increased brain ferritin iron. Ferritin iron can be measured with specificity in vivo with MRI utilizing the field-dependent relaxation rate increase (FDRI) method. FDRI was assessed in three basal ganglia regions (caudate, putamen, and globus pallidus) and frontal lobe white matter for younger- and older-onset male PD and AD patients and healthy controls. Significant increases in basal ganglia FDRI levels were observed in the younger-onset groups of both diseases compared to their respective control groups, but were absent in the older-onset patients. The results support the suggestion that elevated ferritin iron and its associated toxicity is a risk factor for age at onset of neurodegenerative diseases such as AD and PD. Clinical phenomena such as gender-associated risk of developing neurodegenerative diseases and the age at onset of such diseases may be associated with brain iron levels. In vivo MRI can measure and track brain ferritin iron levels and provides an opportunity to design therapeutic interventions that target high-risk populations early in the course of illness, possibly even before symptoms appear.

show abstract

Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease

Cited by 13 publications

References 13 publications

The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications

The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Brain Ferritin Iron as a Risk Factor for Age at Onset in Neurodegenerative Diseases

Contact Info

Product

Resources

About